Molecular testing for somatic mutations in common cancers: The views of UK oncologists

Journal of Clinical Pathology

Volumn 61, Issue 6, 2008, Pages 761-765

  Wordsworth, S ^a   Buchanan, J ^a   Papanicolas, I ^a   Taylor, J ^b   Frayling, I ^c   Tomlinson, I ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOGENETICS; DNA DETERMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL SPECIALIST; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; PHYSICIAN ATTITUDE; PLOIDY; POSTAL MAIL; PRIORITY JOURNAL; QUESTIONNAIRE; SOMATIC MUTATION; UNITED KINGDOM;

ATTITUDE OF HEALTH PERSONNEL; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GREAT BRITAIN; HEMATOLOGY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEDICAL ONCOLOGY; NEOPLASMS; QUESTIONNAIRES;

EID: 45549089779     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.054510     Document Type: Article

References (10)

1. Tomlinson IPM, Ilyas M. Molecular pathology of solid tumours: some practical suggestions for translating research into clinical practice. Mol Pathol 2001;54:203-5.
2. Caldas C. Science, medicine, and the future: molecular assessment of cancer. BMJ 1998;316:1360-3.
3. Carson D, Lois A. Cancer progression and p53. Lancet 1995;346:1009-11.
4. Cole T, Sleightholme H. ABC of colorectal cancer: the role of clinical genetics in management. BMJ 2000;321:943-6.
5. Minamoto T, Ronai Z. Gene mutation as a target for early detection in cancer diagnosis. Crit Rev Oncol Hematol 2001;40:195-213.
6. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41:2060-70.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
9. Clinical Pathology Accreditation (UK). Standards for the medical laboratory. Sheffield: Clinical Pathology Accreditation (UK), 2004.
10. Wordsworth S, Papanicolas I, Buchanan J, et al. Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories. J Clin Pathol 2008;61:373-6.